Comparing ABP 938 With Aflibercept Eye Injections for Neovascular Age-Related Macular Degeneration
Compares ABP 938 8 mg with aflibercept 8 mg for vision in neovascular macular degeneration.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Key facts
- Where
- Albuquerque, Arlington, Austin, Baltimore, Beaufort, Bellaire, Bellevue, Bloomfield, Boston, Carmel, Charleston, Chicago, Colorado Springs, Columbia, Dallas, Dublin, Edina, Elmhurst, Falls Church, Fort Worth, Fullerton, Hagerstown, Houston, Katy, Kingston, Ladson, Lakewood, Liverpool, Long Beach, Madison, Miami, Modesto, Mt. Pleasant, Naples, Nashville, Oceanside, Pasadena, Pensacola, Raleigh, Sacramento, Salt Lake City, San Antonio, Santa Barbara, Scarsdale, Schertz, Silverdale, Spokane, St Louis, Towson, Wake Forest, Waterford, West Columbia, and Willow Park, United StatesSee the 55 sites
- Phase
- Phase 3
Where in United States
- Vision Research Center Eye Associates of New MexicoAlbuquerque, United StatesTaking people
- Texas Retina Associates (TRA) - ArlingtonArlington, United StatesTaking people
- Austin Retina AssociatesAustin, United StatesTaking people
- Austin Retina Associates Ophthalmology/RetinaAustin, United StatesTaking people
- The Retina Care Center- Baltimore (PRISM Vision Group)Baltimore, United StatesTaking people
- Retina Consultants of South Carolina, Charleston Neuroscience institute - Blufffon (RCA)Beaufort, United StatesTaking people
- Retina Consultants of Texas (Bellaire)Bellaire, United StatesTaking people
- Vitreoretinal Associates of WashingtonBellevue, United StatesTaking people
- Envision Ocular, LLCBloomfield, United StatesTaking people
- Ophthalmic Consultants of BostonBoston, United StatesTaking people
- Associated Vitreoretinal and Uveitis ConsultantsCarmel, United StatesTaking people
- Charleston Neuroscience InstituteCharleston, United StatesTaking people
- University Retina - Bedford Park LocationChicago, United StatesTaking people
- Retina Consultants of Southern Colorado (Colorado Springs)- RCAColorado Springs, United StatesTaking people
- Retina Consultants of Southern Colorado (Pueblo)- RCAColorado Springs, United StatesTaking people
- Palmetto Retina Center - Main (RCA)Columbia, United StatesTaking people
- Texas Retina Associates (Tra) - Dallas MainDallas, United StatesTaking people
- Midwest Retina - Main OfficeDublin, United StatesTaking people
- Retina Consultants of Minnesota (RCM) - St. Louis ParkEdina, United StatesTaking people
- Retina AssociatesElmhurst, United StatesTaking people
- Emerson Clinical Research- Virginia Retina SpecialistsFalls Church, United StatesTaking people
- Texas Retina Associates - Fort WorthFort Worth, United StatesTaking people
- Retina Consultants of Orange CountyFullerton, United StatesTaking people
- Mid Atlantic Retina SpecialistsHagerstown, United StatesTaking people
- Retina Consultants of Texas - Katy Retina CenterHouston, United StatesTaking people
- Retina Consultants of Texas - The WoodlandsKaty, United StatesTaking people
- Eye Care Specialists - KingstonKingston, United StatesTaking people
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Ladson (RCA)Ladson, United StatesTaking people
- Colorado Retina Associates (RCA)Lakewood, United StatesTaking people
- Retina Vitreous Surgeons of CNY, PCLiverpool, United StatesTaking people
- South Coast Retina Center - RCALong Beach, United StatesTaking people
- Mississippi Retina AssocMadison, United StatesTaking people
- Medeye Associates - ResearchMiami, United StatesTaking people
- Retinal Consultants Medical Group, Inc - Modesto (RCA)Modesto, United StatesTaking people
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Mount Pleasant (RCA)Mt. Pleasant, United StatesTaking people
- Retina Consultants of Southwest Florida - NaplesNaples, United StatesTaking people
- Tennessee Retina, PCNashville, United StatesTaking people
- Ophthalmic Consultants of Long Island - ResearchOceanside, United StatesTaking people
- California Eye Specialists Medical Group, Inc.Pasadena, United StatesTaking people
- Advanced Research, LLCPensacola, United StatesTaking people
- North Carolina Retina AssociatesRaleigh, United StatesTaking people
- Retinal Consultants Medical Group, Inc - Sacramento - Parkcenter Drive (RCA)Sacramento, United StatesTaking people
- Retina Associates Of Utah Retina SpecialistSalt Lake City, United StatesTaking people
- Retinal Consultants of Texas- San AntonioSan Antonio, United StatesTaking people
- California Retina ConsultantsSanta Barbara, United StatesTaking people
- Long Island Vitreoretinal Consultants(RCA Network)Scarsdale, United StatesTaking people
- Retina Consultants of Texas - SchertzSchertz, United StatesTaking people
- Retina Center NW PLLCSilverdale, United StatesTaking people
- Spokane Eye Clinic (OCT and optical examSpokane, United StatesTaking people
- The Retina Institute, Research Retina Institute (RCA)St Louis, United StatesTaking people
- Retina SpecialistsTowson, United StatesTaking people
- NC Retina Associates- RCAWake Forest, United StatesTaking people
- Retina Group of New EnglandWaterford, United StatesTaking people
- Palmetto Retina Center, Florence (RCA)West Columbia, United StatesTaking people
- Strategic Clinical Research Group, LLCWillow Park, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07614776EU 2025-523500-72-00
- Record updated
- 14 October 2026
- Original description
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)Read full original descriptionShow less
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Inclusion: Men or women ≥ 50 years old, capable of giving signed informed consent; Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE); Total area of CNV (including both classic and occult components) > 50% of the total lesion area in the SE; The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE; Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea.
Exclusion: Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication) in the study eye; Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening; Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins; History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study; Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study; History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye; Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization; History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation; Participants are excluded from the study if any of the following criteria apply at either screening or baseline, unless otherwise indicated per protocol:; Total lesion size > 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye; Scar, fibrosis, or atrophy involving the central subfield in the study eye; Scar or fibrosis involving > 50% of the total lesion in the study eye; Presence of retinal pigment epithelium tears or rips involving the macula in the study eye; Other protocol-specified exclusion criteria.